Manufacturer
BAXTER ONCOLOGY GMBH
Contents
Mitoxantrone HCl
Indication
Breast, ovarian & primary liver cell carcinoma, malignant lymphomas & acute leukaemias.
Instruction
The application of mitoxantrone should only be carried out by a physician specialising in oncology.
IV Application: Mitoxantrone can be administered as a slow IV injection (not less than 5 min).
Mitoxantrone is ideally injected slowly into a well-running IV infusion system. Isotonic saline or a 5% glucose solution are suitable carrier solutions.Mitoxantrone can also be infused for short periods (15-30 min). The calculated dose should be diluted with 50-100 mL of one of the previously mentioned infusion solutions.If a paravenous infiltration occurs, the application should be immediately stopped and restarted using a different point of entry to the vein.So far, only isolated cases of severe local reactions (necroses) have been described due to inadvertent paravenous injection.Intrapleural Instillation: For intrapleural instillation, mitoxantrone is diluted with isotonic sodium chloride solution.The mitoxantrone-containing solution must be warmed to body temperature and instilled very slowly (from 5-10 min), avoiding any noticeable injection pressure.
Duration of Treatment: When a cumulative total dose of 200 mg mitoxantrone/m2 body surface area has been given, the administration of mitoxantrone is to be stopped for all indications.
Drug interaction
Impaired immune response to vaccines may occur; infection after admin of live vaccines in patients on immunosuppressants is also possible.
Malaysia
